-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Transfer from | Medicine Guanlan
On March 20, Boshengji Pharmaceutical Technology (Suzhou) Co.
The advent of CAR-T cell therapy is an important breakthrough in the field of cancer
Neuroblastoma is one of the most common extracranial solid tumors in children with insidious onset and strong heterogeneity
In order to solve the above challenges, the R&D team of Boshengji Pharmaceuticals has developed TAA06 injection in a targeted manner
According to the press release, Boshengji Medicine intends to develop TAA06 injection for the treatment of neuroblastoma
Note: Content has been deleted
Original title: Boshengji CAR-T product obtained FDA orphan drug designation, targeting neuroblastoma!